Sunovion Pharmaceuticals, Inc., will present new clinical and health outcomes data for its Brovana (arformoterol tartrate) Inhalation Solution at the 2016 American Thoracic Society International Conference (ATS 2016), taking place May 13–18 in San Francisco, California. At the ATS meeting, Sunovion will present post-hoc analyses of clinical data generated from its…
BioScale, Inc. has changed its name to ProterixBio, Inc. to mirror the company’s new strategic path centered on high value clinical applications including disease management services and diagnostics products, according to a May 3 news release. ProterixBio is developing pioneering products to transform chronic disease management. The company will…
AstraZeneca recently announced that its bronchodilator inhalation aerosol medicine Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) has been approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), namely, patients suffering from chronic bronchitis and/or emphysema. Bevespi Aerosphere is the…
Sunovion Pharmaceuticals, Inc., recently reported positive data on its Phase 3 clinical development program for SUN-101 (glycopyrrolate) for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). SUN-101 is dispensed using PARI’s investigational and proprietary nebulizer system, called eFlow. Two 12-week, randomized, double-blind, placebo-controlled and parallel-group, Phase 3 efficacy and safety trials (GOLDEN-3 and…
In the first large-scale study comparing the transcriptomics of a variety of lung diseases, Yale scientists revealed that chronic obstructive pulmonary disease (COPD) shares a network of underlying genes with idiopathic pulmonary fibrosis – another devastating lung disease. The new findings advance our understanding of both conditions, and might possibly…
Researchers at the University of Granada (UGR) and Virgen de las Nieves Hospital in Spain revealed that a brief exercise program, from 7 to 10 days, can improve quality of life and physical abilities while minimizing the need for hospitalization in patients with chronic obstructive pulmonary disease (COPD). The research article, “Results…
Aptar Pharma, a global provider of aerosols for healthcare and pharma products, unveiled its latest innovation — the eDose Counter for metered dose inhalers (MDIs) — at the Respiratory Drug Delivery (RDD) Scientific Conference April 17-21 in Phoenix, Arizona. The eDose Counters are engineered to improve treatment adherence in patients…
Propeller Health and AMC Health are partnering to assist patients with chronic obstructive pulmonary disease (COPD) and asthma manage their disease more efficiently and reduce symptoms, as well as hospital visits. The multi-year partnership was signed in January and will kick off this month with the launch of two…
A collaborative research study between several Australian institutions suggests that cigarette smoking and infection with viruses such as influenza can reduce the effectiveness of symptom-reliever drugs like salbutamol in patients with chronic obstructive pulmonary disease (COPD). These findings were published in a research article, “Influenza A virus…
Boehringer Ingelheim recently announced the publication of a new research article detailing the measurement of specific white blood cells, called eosinophils, to prediction the response to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. The study was developed using data from the…
Get regular updates to your inbox.